Global Cannabinoid Biosynthesis Market

Cannabinoid Biosynthesis Comprehensive Study by Application (Epilepsy, Cancer Chemotherapy, Nausea and Vomiting, Appetite Stimulation, Other), Drug (Cannabidiol, Tetrahydrocannabinol, Cannabigerol, Tetrahydrocannabivarin, Others), End Users (Pharmaceutical Companies, Hospitals, Clinics), Distribution Channel (Online {Company Website, E-Commerce Website}, Offline {Hospital Pharmacy, Medical Stores}) Players and Region - Global Market Outlook to 2028

Cannabinoid Biosynthesis Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Cannabinoid Biosynthesis Market Scope?
Biosynthetic Cannabinoids (such as CBD) are cannabinoids that are created in the lab utilizing biosynthesis technology, rather than being synthesized from man-made compounds or extracted directly from cannabis or hemp material. Cannabinoid biosynthesis is extremely modular, allowing for the utilization of modules found in synthetic biology-based combinatorial techniques, as evidenced by the creation of novel-to-nature cannabinoids in Saccharomyces cerevisiae.

Influencing Trend:
Rise in Prevalence of Cannabinoid Designer Drugs

Market Growth Drivers:
Rising Legalisation of Cannabis and Cannabinoid Products Across the Globe and Increase in Demand for On-Psychoactive Cannabinoid Extracts of the Cannabis Plant

Challenges:
Cannabis Cultivation has an Enormous Carbon Footprint

Restraints:
Cannabinoid Biosynthesis may Cause Severe Side Effects such as Rapid Heart Rate, Vomiting, Agitation, Confusion, And Hallucinations

Opportunities:
Increasing Research and Development by Pharmaceutical Industry

The Cannabinoid Biosynthesis market study is being classified, by Application and major geographies with country level break-up.

The demand for Cannabinoid Biosynthesis is increasing with each passing day. Companies in this industry are facing significant constraints. Many worldwide and regional service providers participate in the sector and compete directly with industry leaders. It has been identified that market-leading players are investing heavily in technological development, and resource utilization to boost their market position. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Cannabinoid Biosynthesis market throughout the predicted period.

Creo (United States), Deloitte (United Kingdom), Demetria (United States), Precigen (United States), Hyasynth Biologicals Inc. (Canada), Willow Biosciences (Canada), Ginkgo Bioworks (United States), CB Therapeutics (United States), InMed Pharmaceuticals (Canada) and Surterra (Unites States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Lavvan (United States), Librede (United States) and BayMedica (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Cannabinoid Biosynthesis market by Type, Application and Region.

On the basis of geography, the market of Cannabinoid Biosynthesis has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Influencers and their Development Strategies
In February 2021, Jazz Pharmaceuticals announced to the acquisition of GW Pharmaceutical Plc. GW is one of the key players in discovering, developing, manufacturing, and commercializing novel, regulatory-approved therapeutics from its proprietary cannabinoid product platform to address a broad range of diseases.

European Union, the cultivation and processing of cannabis and hemp plants is regulated by individual member states, although there are some EU-wide regulations related to the safety and quality of food and medicine products that may apply to cannabinoids produced through biosynthesis.

Key Target Audience
Venture and Capitalist, New Entrants/Investors, Analysts and Strategic Business Partners, Raw Material Suppliers and Distributors, Healthcare and End-Use Industries

Cannabinoid Biosynthesis Market Study: Important Years
AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Major Highlights of Market Study

Demand Determinants: Identifying top-notch application and business segments that seek high growth potentials in Cannabinoid Biosynthesis Market.

Key Strategic Developments: To target untapped regions more aggressively by focusing on product/service developments, innovation and R & D, new launches, Merger & acquisitions, JVs & partnerships.

Forces & Market Dynamics: Growth drivers, restraints & opportunities available in Cannabinoid Biosynthesis industry is examined with reference relevant market sectors and sub-sectors.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also includes significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets, To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Application
  • Epilepsy
  • Cancer Chemotherapy
  • Nausea and Vomiting
  • Appetite Stimulation
  • Other
By Drug
  • Cannabidiol
  • Tetrahydrocannabinol
  • Cannabigerol
  • Tetrahydrocannabivarin
  • Others

By End Users
  • Pharmaceutical Companies
  • Hospitals
  • Clinics

By Distribution Channel
  • Online {Company Website, E-Commerce Website}
  • Offline {Hospital Pharmacy, Medical Stores}

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Legalisation of Cannabis and Cannabinoid Products Across the Globe
      • 3.2.2. Increase in Demand for On-Psychoactive Cannabinoid Extracts of the Cannabis Plant
    • 3.3. Market Challenges
      • 3.3.1. Cannabis Cultivation has an Enormous Carbon Footprint
    • 3.4. Market Trends
      • 3.4.1. Rise in Prevalence of Cannabinoid Designer Drugs
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cannabinoid Biosynthesis, by Application, Drug, End Users, Distribution Channel and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Cannabinoid Biosynthesis (Value)
      • 5.2.1. Global Cannabinoid Biosynthesis by: Application (Value)
        • 5.2.1.1. Epilepsy
        • 5.2.1.2. Cancer Chemotherapy
        • 5.2.1.3. Nausea and Vomiting
        • 5.2.1.4. Appetite Stimulation
        • 5.2.1.5. Other
      • 5.2.2. Global Cannabinoid Biosynthesis by: Drug (Value)
        • 5.2.2.1. Cannabidiol
        • 5.2.2.2. Tetrahydrocannabinol
        • 5.2.2.3. Cannabigerol
        • 5.2.2.4. Tetrahydrocannabivarin
        • 5.2.2.5. Others
      • 5.2.3. Global Cannabinoid Biosynthesis by: End Users (Value)
        • 5.2.3.1. Pharmaceutical Companies
        • 5.2.3.2. Hospitals
        • 5.2.3.3. Clinics
      • 5.2.4. Global Cannabinoid Biosynthesis by: Distribution Channel (Value)
        • 5.2.4.1. Online {Company Website, E-Commerce Website}
        • 5.2.4.2. Offline {Hospital Pharmacy, Medical Stores}
      • 5.2.5. Global Cannabinoid Biosynthesis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Cannabinoid Biosynthesis (Price)
  • 6. Cannabinoid Biosynthesis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Creo (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Deloitte (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Demetria (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Precigen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Hyasynth Biologicals Inc. (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Willow Biosciences (Canada)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Ginkgo Bioworks (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. CB Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. InMed Pharmaceuticals (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Surterra (Unites States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Cannabinoid Biosynthesis Sale, by Application, Drug, End Users, Distribution Channel and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Cannabinoid Biosynthesis (Value)
      • 7.2.1. Global Cannabinoid Biosynthesis by: Application (Value)
        • 7.2.1.1. Epilepsy
        • 7.2.1.2. Cancer Chemotherapy
        • 7.2.1.3. Nausea and Vomiting
        • 7.2.1.4. Appetite Stimulation
        • 7.2.1.5. Other
      • 7.2.2. Global Cannabinoid Biosynthesis by: Drug (Value)
        • 7.2.2.1. Cannabidiol
        • 7.2.2.2. Tetrahydrocannabinol
        • 7.2.2.3. Cannabigerol
        • 7.2.2.4. Tetrahydrocannabivarin
        • 7.2.2.5. Others
      • 7.2.3. Global Cannabinoid Biosynthesis by: End Users (Value)
        • 7.2.3.1. Pharmaceutical Companies
        • 7.2.3.2. Hospitals
        • 7.2.3.3. Clinics
      • 7.2.4. Global Cannabinoid Biosynthesis by: Distribution Channel (Value)
        • 7.2.4.1. Online {Company Website, E-Commerce Website}
        • 7.2.4.2. Offline {Hospital Pharmacy, Medical Stores}
      • 7.2.5. Global Cannabinoid Biosynthesis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Cannabinoid Biosynthesis (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cannabinoid Biosynthesis: by Application(USD Million)
  • Table 2. Cannabinoid Biosynthesis Epilepsy , by Region USD Million (2017-2022)
  • Table 3. Cannabinoid Biosynthesis Cancer Chemotherapy , by Region USD Million (2017-2022)
  • Table 4. Cannabinoid Biosynthesis Nausea and Vomiting , by Region USD Million (2017-2022)
  • Table 5. Cannabinoid Biosynthesis Appetite Stimulation , by Region USD Million (2017-2022)
  • Table 6. Cannabinoid Biosynthesis Other , by Region USD Million (2017-2022)
  • Table 7. Cannabinoid Biosynthesis: by Drug(USD Million)
  • Table 8. Cannabinoid Biosynthesis Cannabidiol , by Region USD Million (2017-2022)
  • Table 9. Cannabinoid Biosynthesis Tetrahydrocannabinol , by Region USD Million (2017-2022)
  • Table 10. Cannabinoid Biosynthesis Cannabigerol , by Region USD Million (2017-2022)
  • Table 11. Cannabinoid Biosynthesis Tetrahydrocannabivarin , by Region USD Million (2017-2022)
  • Table 12. Cannabinoid Biosynthesis Others , by Region USD Million (2017-2022)
  • Table 13. Cannabinoid Biosynthesis: by End Users(USD Million)
  • Table 14. Cannabinoid Biosynthesis Pharmaceutical Companies , by Region USD Million (2017-2022)
  • Table 15. Cannabinoid Biosynthesis Hospitals , by Region USD Million (2017-2022)
  • Table 16. Cannabinoid Biosynthesis Clinics , by Region USD Million (2017-2022)
  • Table 17. Cannabinoid Biosynthesis: by Distribution Channel(USD Million)
  • Table 18. Cannabinoid Biosynthesis Online {Company Website, E-Commerce Website} , by Region USD Million (2017-2022)
  • Table 19. Cannabinoid Biosynthesis Offline {Hospital Pharmacy, Medical Stores} , by Region USD Million (2017-2022)
  • Table 20. South America Cannabinoid Biosynthesis, by Country USD Million (2017-2022)
  • Table 21. South America Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 22. South America Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 23. South America Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 24. South America Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 25. Brazil Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 26. Brazil Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 27. Brazil Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 28. Brazil Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 29. Argentina Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 30. Argentina Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 31. Argentina Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 32. Argentina Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 33. Rest of South America Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 34. Rest of South America Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 35. Rest of South America Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 36. Rest of South America Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 37. Asia Pacific Cannabinoid Biosynthesis, by Country USD Million (2017-2022)
  • Table 38. Asia Pacific Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 39. Asia Pacific Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 40. Asia Pacific Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 41. Asia Pacific Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 42. China Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 43. China Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 44. China Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 45. China Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 46. Japan Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 47. Japan Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 48. Japan Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 49. Japan Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 50. India Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 51. India Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 52. India Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 53. India Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 54. South Korea Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 55. South Korea Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 56. South Korea Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 57. South Korea Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 58. Australia Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 59. Australia Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 60. Australia Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 61. Australia Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 62. Rest of Asia-Pacific Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 63. Rest of Asia-Pacific Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 66. Europe Cannabinoid Biosynthesis, by Country USD Million (2017-2022)
  • Table 67. Europe Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 68. Europe Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 69. Europe Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 70. Europe Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 71. Germany Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 72. Germany Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 73. Germany Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 74. Germany Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 75. France Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 76. France Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 77. France Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 78. France Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 79. Italy Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 80. Italy Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 81. Italy Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 82. Italy Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 83. United Kingdom Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 84. United Kingdom Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 85. United Kingdom Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 86. United Kingdom Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 87. Netherlands Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 88. Netherlands Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 89. Netherlands Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 90. Netherlands Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 91. Rest of Europe Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 92. Rest of Europe Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 93. Rest of Europe Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 94. Rest of Europe Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 95. MEA Cannabinoid Biosynthesis, by Country USD Million (2017-2022)
  • Table 96. MEA Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 97. MEA Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 98. MEA Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 99. MEA Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 100. Middle East Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 101. Middle East Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 102. Middle East Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 103. Middle East Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 104. Africa Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 105. Africa Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 106. Africa Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 107. Africa Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 108. North America Cannabinoid Biosynthesis, by Country USD Million (2017-2022)
  • Table 109. North America Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 110. North America Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 111. North America Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 112. North America Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 113. United States Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 114. United States Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 115. United States Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 116. United States Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 117. Canada Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 118. Canada Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 119. Canada Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 120. Canada Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 121. Mexico Cannabinoid Biosynthesis, by Application USD Million (2017-2022)
  • Table 122. Mexico Cannabinoid Biosynthesis, by Drug USD Million (2017-2022)
  • Table 123. Mexico Cannabinoid Biosynthesis, by End Users USD Million (2017-2022)
  • Table 124. Mexico Cannabinoid Biosynthesis, by Distribution Channel USD Million (2017-2022)
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Cannabinoid Biosynthesis: by Application(USD Million)
  • Table 136. Cannabinoid Biosynthesis Epilepsy , by Region USD Million (2023-2028)
  • Table 137. Cannabinoid Biosynthesis Cancer Chemotherapy , by Region USD Million (2023-2028)
  • Table 138. Cannabinoid Biosynthesis Nausea and Vomiting , by Region USD Million (2023-2028)
  • Table 139. Cannabinoid Biosynthesis Appetite Stimulation , by Region USD Million (2023-2028)
  • Table 140. Cannabinoid Biosynthesis Other , by Region USD Million (2023-2028)
  • Table 141. Cannabinoid Biosynthesis: by Drug(USD Million)
  • Table 142. Cannabinoid Biosynthesis Cannabidiol , by Region USD Million (2023-2028)
  • Table 143. Cannabinoid Biosynthesis Tetrahydrocannabinol , by Region USD Million (2023-2028)
  • Table 144. Cannabinoid Biosynthesis Cannabigerol , by Region USD Million (2023-2028)
  • Table 145. Cannabinoid Biosynthesis Tetrahydrocannabivarin , by Region USD Million (2023-2028)
  • Table 146. Cannabinoid Biosynthesis Others , by Region USD Million (2023-2028)
  • Table 147. Cannabinoid Biosynthesis: by End Users(USD Million)
  • Table 148. Cannabinoid Biosynthesis Pharmaceutical Companies , by Region USD Million (2023-2028)
  • Table 149. Cannabinoid Biosynthesis Hospitals , by Region USD Million (2023-2028)
  • Table 150. Cannabinoid Biosynthesis Clinics , by Region USD Million (2023-2028)
  • Table 151. Cannabinoid Biosynthesis: by Distribution Channel(USD Million)
  • Table 152. Cannabinoid Biosynthesis Online {Company Website, E-Commerce Website} , by Region USD Million (2023-2028)
  • Table 153. Cannabinoid Biosynthesis Offline {Hospital Pharmacy, Medical Stores} , by Region USD Million (2023-2028)
  • Table 154. South America Cannabinoid Biosynthesis, by Country USD Million (2023-2028)
  • Table 155. South America Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 156. South America Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 157. South America Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 158. South America Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 159. Brazil Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 160. Brazil Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 161. Brazil Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 162. Brazil Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 163. Argentina Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 164. Argentina Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 165. Argentina Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 166. Argentina Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 167. Rest of South America Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 168. Rest of South America Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 169. Rest of South America Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 170. Rest of South America Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 171. Asia Pacific Cannabinoid Biosynthesis, by Country USD Million (2023-2028)
  • Table 172. Asia Pacific Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 173. Asia Pacific Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 174. Asia Pacific Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 175. Asia Pacific Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 176. China Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 177. China Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 178. China Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 179. China Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 180. Japan Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 181. Japan Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 182. Japan Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 183. Japan Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 184. India Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 185. India Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 186. India Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 187. India Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 188. South Korea Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 189. South Korea Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 190. South Korea Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 191. South Korea Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 192. Australia Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 193. Australia Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 194. Australia Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 195. Australia Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 196. Rest of Asia-Pacific Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 197. Rest of Asia-Pacific Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 198. Rest of Asia-Pacific Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 199. Rest of Asia-Pacific Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 200. Europe Cannabinoid Biosynthesis, by Country USD Million (2023-2028)
  • Table 201. Europe Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 202. Europe Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 203. Europe Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 204. Europe Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 205. Germany Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 206. Germany Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 207. Germany Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 208. Germany Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 209. France Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 210. France Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 211. France Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 212. France Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 213. Italy Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 214. Italy Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 215. Italy Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 216. Italy Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 217. United Kingdom Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 218. United Kingdom Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 219. United Kingdom Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 220. United Kingdom Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 221. Netherlands Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 222. Netherlands Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 223. Netherlands Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 224. Netherlands Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 225. Rest of Europe Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 226. Rest of Europe Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 227. Rest of Europe Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 228. Rest of Europe Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 229. MEA Cannabinoid Biosynthesis, by Country USD Million (2023-2028)
  • Table 230. MEA Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 231. MEA Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 232. MEA Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 233. MEA Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 234. Middle East Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 235. Middle East Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 236. Middle East Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 237. Middle East Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 238. Africa Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 239. Africa Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 240. Africa Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 241. Africa Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 242. North America Cannabinoid Biosynthesis, by Country USD Million (2023-2028)
  • Table 243. North America Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 244. North America Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 245. North America Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 246. North America Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 247. United States Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 248. United States Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 249. United States Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 250. United States Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 251. Canada Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 252. Canada Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 253. Canada Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 254. Canada Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 255. Mexico Cannabinoid Biosynthesis, by Application USD Million (2023-2028)
  • Table 256. Mexico Cannabinoid Biosynthesis, by Drug USD Million (2023-2028)
  • Table 257. Mexico Cannabinoid Biosynthesis, by End Users USD Million (2023-2028)
  • Table 258. Mexico Cannabinoid Biosynthesis, by Distribution Channel USD Million (2023-2028)
  • Table 259. Research Programs/Design for This Report
  • Table 260. Key Data Information from Secondary Sources
  • Table 261. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cannabinoid Biosynthesis: by Application USD Million (2017-2022)
  • Figure 5. Global Cannabinoid Biosynthesis: by Drug USD Million (2017-2022)
  • Figure 6. Global Cannabinoid Biosynthesis: by End Users USD Million (2017-2022)
  • Figure 7. Global Cannabinoid Biosynthesis: by Distribution Channel USD Million (2017-2022)
  • Figure 8. South America Cannabinoid Biosynthesis Share (%), by Country
  • Figure 9. Asia Pacific Cannabinoid Biosynthesis Share (%), by Country
  • Figure 10. Europe Cannabinoid Biosynthesis Share (%), by Country
  • Figure 11. MEA Cannabinoid Biosynthesis Share (%), by Country
  • Figure 12. North America Cannabinoid Biosynthesis Share (%), by Country
  • Figure 13. Global Cannabinoid Biosynthesis share by Players 2022 (%)
  • Figure 14. Global Cannabinoid Biosynthesis share by Players (Top 3) 2022(%)
  • Figure 15. Global Cannabinoid Biosynthesis share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Creo (United States) Revenue, Net Income and Gross profit
  • Figure 18. Creo (United States) Revenue: by Geography 2022
  • Figure 19. Deloitte (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Deloitte (United Kingdom) Revenue: by Geography 2022
  • Figure 21. Demetria (United States) Revenue, Net Income and Gross profit
  • Figure 22. Demetria (United States) Revenue: by Geography 2022
  • Figure 23. Precigen (United States) Revenue, Net Income and Gross profit
  • Figure 24. Precigen (United States) Revenue: by Geography 2022
  • Figure 25. Hyasynth Biologicals Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 26. Hyasynth Biologicals Inc. (Canada) Revenue: by Geography 2022
  • Figure 27. Willow Biosciences (Canada) Revenue, Net Income and Gross profit
  • Figure 28. Willow Biosciences (Canada) Revenue: by Geography 2022
  • Figure 29. Ginkgo Bioworks (United States) Revenue, Net Income and Gross profit
  • Figure 30. Ginkgo Bioworks (United States) Revenue: by Geography 2022
  • Figure 31. CB Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 32. CB Therapeutics (United States) Revenue: by Geography 2022
  • Figure 33. InMed Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 34. InMed Pharmaceuticals (Canada) Revenue: by Geography 2022
  • Figure 35. Surterra (Unites States) Revenue, Net Income and Gross profit
  • Figure 36. Surterra (Unites States) Revenue: by Geography 2022
  • Figure 37. Global Cannabinoid Biosynthesis: by Application USD Million (2023-2028)
  • Figure 38. Global Cannabinoid Biosynthesis: by Drug USD Million (2023-2028)
  • Figure 39. Global Cannabinoid Biosynthesis: by End Users USD Million (2023-2028)
  • Figure 40. Global Cannabinoid Biosynthesis: by Distribution Channel USD Million (2023-2028)
  • Figure 41. South America Cannabinoid Biosynthesis Share (%), by Country
  • Figure 42. Asia Pacific Cannabinoid Biosynthesis Share (%), by Country
  • Figure 43. Europe Cannabinoid Biosynthesis Share (%), by Country
  • Figure 44. MEA Cannabinoid Biosynthesis Share (%), by Country
  • Figure 45. North America Cannabinoid Biosynthesis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Creo (United States)
  • Deloitte (United Kingdom)
  • Demetria (United States)
  • Precigen (United States)
  • Hyasynth Biologicals Inc. (Canada)
  • Willow Biosciences (Canada)
  • Ginkgo Bioworks (United States)
  • CB Therapeutics (United States)
  • InMed Pharmaceuticals (Canada)
  • Surterra (Unites States)
Additional players considered in the study are as follows:
Lavvan (United States) , Librede (United States) , BayMedica (United States)
Select User Access Type

Key Highlights of Report


May 2023 231 Pages 67 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Cannabinoid Biosynthesis Market Quantitative research analysis
Global Cannabinoid Biosynthesis Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The prominent players of Global Cannabinoid Biosynthesis market are Creo (United States), Deloitte (United Kingdom), Demetria (United States), Precigen (United States), Hyasynth Biologicals Inc. (Canada), Willow Biosciences (Canada), Ginkgo Bioworks (United States), CB Therapeutics (United States), InMed Pharmaceuticals (Canada) and Surterra (Unites States).
In this highly competitive & fast evolving Cannabinoid Biosynthesis industry, the top strategic priorities would remain consistent like innovation, R&D, and M&A.
Epilepsy, Cancer Chemotherapy, Nausea and Vomiting, Appetite Stimulation and Other are the potential customers of Cannabinoid Biosynthesis industry.

Know More About Global Cannabinoid Biosynthesis Market Report?

Have a Query? Click Here

Other Related Reports

Airlift Bioreactors Comprehensive Study by Type (Internal Airlift Loop Bioreactor, External Airlift Loop Bioreactor), Usage (Disposal, Reusable), Capacity (5L, 7L, 10L, 30L), Material (Stainless Stee...
$ 3450
Osteoarthritis Gene Therapy Comprehensive Study by Type (Synovium Injection, Cartilage Injection), Vectors (Non-viral, Retrovirus, Lentivirus, Adenovirus, Adeno-associated virus (AAV), HSV), End User...
$ 3800
Virology Comprehensive Study by Application (Medicine, Agriculture, Nanotechnology, Others), Diagnosis Test (Hepatitis B, Hepatitis C, HIV, Other), Disease (AIDS, Common Cold, Ebola, Genital Herpes, ...
$ 3500
Biotechnology Reagents & Kits Comprehensive Study by Type (Purification Kits, Amplification Kits, Detection Kits, Isolation Kits, Others), Micro-Organisms (Bacteria, Virus, Fungi, Parasites), Technol...
$ 3800
Virology Specimen Collection Comprehensive Study by Application (Diagnostics, Research), End-users (Hospitals & Clinics, Diagnostic Centers, Others), Samples (Blood Samples, Nasopharyngeal Samples, T...
$ 3500
Biotechnology Services Comprehensive Study by Application (Pharmaceutical, Clinical Trial, Healthcare Sectors), Technology (Tissue Engineering and Regeneration, PCR Technology, Nano Biotechnology, Ch...
$ 3500